What is the 13F Pro Quality Score for MNOV?

13F Pro ranks MEDICINOVA INC (MNOV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MNOV's current score at https://13fpro.ai/company/MNOV (free sign-up required for the full ranking).

Which hedge funds own the most MNOV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MNOV include Essex Woodlands Management,, BlackRock,, CITIGROUP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MNOV as soon as new 13F filings post.

Where does 13F Pro source MNOV data?

All MEDICINOVA INC fundamentals and ownership data come directly from SEC EDGAR. MEDICINOVA INC files with the SEC under CIK 1226616. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MNOV in?

MEDICINOVA INC (MNOV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MNOV research updated on 13F Pro?

MNOV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MEDICINOVA INC(MNOV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1226616 MNOV stock profile & AI dashboard →

13F Pro Quality Score

13.0/100

Rank #2,878 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MNOV Scores 13/100

exact factor attribution · 2026-09-11

MNOV's composite is driven by earnings growth, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.2 pts

95th pct

Institutional flow

-1.3 pts

23th pct

Shareholder dilution

-2.3 pts

4th pct

Earnings quality

-2.7 pts

23th pct

Capital efficiency

-3.4 pts

16th pct

Profitability

-6.7 pts

5th pct

Free cash flow

-6.9 pts

4th pct

Scale

-7.2 pts

2th pct

Revenue growth

-8.7 pts

6th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MNOV Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for MEDICINOVA INC (MNOV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MNOV at 13.0/100 on a 32-signal composite quality model, placing it at rank #2,878 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), MEDICINOVA INC reports quarterly revenue of $458.4K, net income of $-2.3M, free cash flow of $-1.9M. Top institutional holders of MNOV by reported 13-F value include Essex Woodlands Management, BlackRock, CITIGROUP, based on the most recent SEC filings. MNOV trades on the Nasdaq exchange and files with the SEC under CIK 1226616. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MNOV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MEDICINOVA INC directly from SEC EDGAR. MEDICINOVA INC's 13F Pro composite quality score has ranged between 13 and 57 since 2026, currently 13.0 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about MEDICINOVA INC

Quirks, history, and lore behind MNOV — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Southern California · focused on developing drugs for serious unmet medical needs.
2
The Numbers
With a micro-cap market value and minimal revenue, this company runs lean — its pipeline is its entire balance sheet, for better or worse.
3
The History
Founded in the early 2000s, it was built around in-licensing compounds from Japanese pharmaceutical companies and advancing them through U.S. clinical trials.
4
The Secret
Its lead compounds have targeted conditions ranging from addiction and withdrawal to respiratory diseases — including research tied to COVID-19-related lung injury.
5
The Lore
The company has a distinctly U.S.–Japan bridge identity, drawing on partnerships and science from Japanese pharma to feed an American regulatory pipeline.
6
The Giveaway
Its ticker is MNOV, its name fuses 'medicine' and 'nova' (as in new), and its most advanced asset has been studied for methamphetamine use disorder — a condition almost no one else is chasing.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$458.4K

Net Income

Q2 2026

$-2.3M

Free Cash Flow

Q2 2026

$-1.9M

ROIC

Q2 2026

-27.3%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

$409.7KFY 2025

FY22 —FY23 $1.0MFY24 —FY25 $409.7K

Net Income

-8.6% YoY

$-12.0MFY 2025

FY22 $-14.1MFY23 $-8.6MFY24 $-11.0MFY25 $-12.0M

Operating Income

-4.8% YoY

$-13.3MFY 2025

FY22 $-14.6MFY23 $-9.9MFY24 $-12.7MFY25 $-13.3M

EPS (Diluted)

-4.3% YoY

$-0.24FY 2025

FY22 $-0.29FY23 $-0.17FY24 $-0.23FY25 $-0.24

Total Assets

-18.4% YoY

$45.6MFY 2025

FY22 $74.2MFY23 $66.3MFY24 $55.9MFY25 $45.6M

Op. Cash Flow

+7.8% YoY

$-9.8MFY 2025

FY22 $-12.9MFY23 $-7.4MFY24 $-10.6MFY25 $-9.8M

Free Cash Flow

+7.8% YoY

$-9.8MFY 2025

FY22 $-12.9MFY23 $-7.5MFY24 $-10.6MFY25 $-9.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$409.7K	—	$1.0M	—	$4.0M	—
Net Income	$-12.0M -8.6%	$-11.0M -28.9%	$-8.6M +39.1%	$-14.1M -38.8%	$-10.1M +26.8%	$-13.9M
Operating Income	$-13.3M -4.8%	$-12.7M -28.0%	$-9.9M +32.3%	$-14.6M -43.2%	$-10.2M +27.9%	$-14.2M
EPS (Diluted)	$-0.24 -4.3%	$-0.23 -35.3%	$-0.17 +41.4%	$-0.29 -38.1%	$-0.21	—
Total Assets	$45.6M -18.4%	$55.9M -15.7%	$66.3M -10.6%	$74.2M -15.2%	$87.4M +15.9%	$75.4M
Operating Cash Flow	$-9.8M +7.8%	$-10.6M -43.2%	$-7.4M +42.4%	$-12.9M -37.6%	$-9.4M +13.3%	$-10.8M
Free Cash Flow	$-9.8M +7.8%	$-10.6M -42.8%	$-7.5M +42.3%	$-12.9M -37.3%	$-9.4M +13.4%	$-10.9M

Get alerted when MNOV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MEDICINOVA INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MNOV

Essex Woodlands Management, Inc.
$1.5M1,105,941 sh
BlackRock, Inc.
$992.8K752,091 sh
CITIGROUP INC
$839.1K635,715 sh
VANGUARD CAPITAL MANAGEMENT LLC
$803.9K609,052 sh
GEODE CAPITAL MANAGEMENT, LLC
$712.1K539,312 sh
VANGUARD FIDUCIARY TRUST CO
$373.0K282,608 sh
UBS Group AG
$293.3K222,200 sh
RENAISSANCE TECHNOLOGIES LLC
$271.1K205,400 sh
STATE STREET CORP
$255.7K193,698 sh
NORTHERN TRUST CORP
$189.6K143,665 sh

Fund	Value	Shares
Essex Woodlands Management, Inc.	$1.5M	1,105,941
BlackRock, Inc.	$992.8K	752,091
CITIGROUP INC	$839.1K	635,715
VANGUARD CAPITAL MANAGEMENT LLC	$803.9K	609,052
GEODE CAPITAL MANAGEMENT, LLC	$712.1K	539,312
VANGUARD FIDUCIARY TRUST CO	$373.0K	282,608
UBS Group AG	$293.3K	222,200
RENAISSANCE TECHNOLOGIES LLC	$271.1K	205,400
STATE STREET CORP	$255.7K	193,698
NORTHERN TRUST CORP	$189.6K	143,665

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MNOV on your watchlist

Track score changes the day MEDICINOVA INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MNOV a good stock to buy?

13F Pro's AI-powered analysis of MEDICINOVA INC (MNOV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MNOV are available on the MNOV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MNOV is classified as a small company.

Which hedge funds own MNOV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MNOV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MEDICINOVA INC's investment landscape.